Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites

Atopic Asthma Clinical Trial

— 18-03 EONOV  

Official title:

Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03665701
• Other study ID #: 18-03 EONOV
• Status: Completed
• Phase: N/A
• Start date: August 16, 2018
• Est. completion date: December 16, 2019

Study information

• Verified date: June 2020
• Source: Fraunhofer-Institute of Toxicology and Experimental Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to draw blood from patients with well-defined atopic asthma that will be subsequently used in invitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2. The inhibitory activity of a potent DP2 receptor antagonist, Fevipripant, shall be determined.

Description:

The inhibitory activity of a potent DP2 receptor antagonist shall be determined. For these experiments eosinophil granulocytes and ILC2 cells will be isolated from the collected blood samples and used in specific assays in respect to their functional reactivity against the DP2 receptor antagonist Fevipiprant after respective stimulation using Prostaglandin D2 metabolites or Prostaglandin D2. Major rationale is to show and determine the EC70 of the effectivity of Fevipiprant against Prostaglandin D2 metabolite triggered activation of eosinophil granulocytes and ILC2 innate lymphoid cells.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: December 16, 2019
• Est. primary completion date: December 16, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Women will be considered for inclusion if they are:

Not pregnant, as confirmed by pregnancy test (see flow chart), and not nursing. Of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal, with documented proof of hysterectomy or tubal ligation, or meets clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the screening visit).

Of childbearing potential and using a highly effective method of contraception during the entire study (vasectomised partner, sexual abstinence - the lifestyle of the female should be such that there is complete abstinence from intercourse from two weeks prior to the first dose of study medication until at least 72 hours after treatment -, implants, injectables, combined oral contraceptives, hormonal IUDs or double-barrier methods, i.e. any double combination of IUD, condom with spermicidal gel, diaphragm, sponge, and cervical cap).

• Body weight = 50 kg and BMI within the range 19-32 kg/m²

• History of allergic asthma since at least 12 months

• A concentration of at least 0,15 x 106/mL eosinophils in peripheral blood

Exclusion Criteria:

• History of an acute infection two weeks prior to the screening visit.

• Intake of oral steroids within 4 weeks prior to screening

• Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis).

• Participation in another clinical trial 30 days prior to enrollment.

• Donation of more than 100 ml of blood in the preceding 2 months before the screening visit.

Related Conditions & MeSH terms

• Atopic Asthma

Intervention

Procedure:
• Blood Sampling
Blood samples used within in vitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2.

Locations

Country	Name	City	State
Germany	Fraunhofer ITEM im CRC	Hannover	Niedersachsen

Sponsors (1)

Lead Sponsor	Collaborator
Fraunhofer-Institute of Toxicology and Experimental Medicine

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cytokinesecretion without presence of Fevipiprant	Cytokine release after exposure of ILC2 cells to prostaglandin D2	4 hours after in-vitro exposure of ILC2 cells to prostaglandin D2
Primary	Cytokinesecretion with presence of Fevipiprant	Cytokine release after exposure of ILC2 cells to prostaglandin D2	4 hours after in-vitro exposure of ILC2 cells to prostaglandin D2